

LA JOLLA PHARMACEUTICAL CO

Form 8-K

August 18, 2004

**Table of Contents**

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, DC 20549**

**FORM 8-K**

**CURRENT REPORT  
Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934**

Date of report (Date of earliest event reported): August 11, 2004

**LA JOLLA PHARMACEUTICAL COMPANY**

(Exact Name of Registrant as Specified in Charter)

Delaware  
(State or Other Jurisdiction  
of Incorporation)

0-24274  
(Commission  
File Number)

33-0361285  
(IRS Employer  
Identification No.)

6455 Nancy Ridge Drive  
San Diego, California 92121  
(Address of Principal Executive Offices, including Zip Code)

(858) 452-6600  
(Registrant's telephone number, including area code)

---

**TABLE OF CONTENTS**

Item 5. Other Events and Required FD Disclosure.

SIGNATURES

---

**Table of Contents**

**Item 5. Other Events and Required FD Disclosure.**

On August 11, 2004, the board of directors of La Jolla Pharmaceutical Company (the Company ) accepted the resignation of William R. Ringo from the board. Mr. Ringo informed the board that he would be assuming the role of President and CEO of Abgenix, Inc. effective August 30, 2004 and that he desired to retire from the board of directors of the Company in order to focus his efforts on his new positions. Mr. Ringo will continue to serve on the board until September 1, 2004.

---

**Table of Contents**

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: August 18, 2004

**LA JOLLA PHARMACEUTICAL  
COMPANY**

By: /s/ Gail A. Sloan  
Gail A. Sloan  
Vice President Finance, Controller and  
Secretary